SUMMARY

OncologySTAT Editorial Team

Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF). It is thought to decrease nitric oxide synthesis, leading to constriction of the vasculature and reduced sodium ion renal excretion, which ultimately leads to hypertension. This suggests that the onset of hypertension during treatment with bevacizumab may be a sign of effective inhibition of VEGF and a predictor of improved outcomes. Dahlberg et al examined this hypothesis by analyzing blood pressure (BP)...